Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: The role of high-sensitivity C-reactive protein

Chest

Volumn 126, Issue 4, 2004, Pages 1032-1039

  Leu, Hsin Bang ^a   Lin, Chih Pei ^a   Lin, Wen Tasi ^a   Wu, Tao Cheng ^a   Chen, Jaw Wen ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

C reactive protein; Cholesterol; Coronary artery disease; High density lipoprotein cholesterol; Homocysteine

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VON WILLEBRAND FACTOR;

ADULT; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 6344249007     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.4.1032     Document Type: Article

References (42)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126
2. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary prevention; identifying the high-risk patient for primary prevention; noninvasive tests of atherosclerotic burden. Writing Group III. Circulation 2000; 101:E16-E22
3. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: multiple risk factor intervention trial. Am J Epidemiol 1996; 144:537-547
4. Bholasingh R, de Winter RJ, Fischer JC, et al. Safe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MB(mass). Heart 2001; 85:143-148
5. Retterstol L, Eikvar L, Bohn M, et al. C-reactive protein predicts death in patients with previous premature myocardial infarction: a 10 year follow-up study. Atherosclerosis 2002; 160:433-440
6. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002; 40:49-55
7. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55:44-5-451
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809
9. Hodish I, Matetzky S, Selah BA, et al. Effect of elevated homocysteine levels on clinical restenosis following percutaneous coronary intervention. Cardiology 2002; 97:214-217
10. Pearson TA. New tools for coronary risk assessment: what are their advantages and limitations? Circulation 2002; 105:886-892
11. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the global evaluation of new events and restenosis after stent implantation study. J Am Coll Cardiol 2002; 40:1375
12. Nurk E, Tell GS, Vollset SE, et al. Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med 2002; 162:1374-1381
13. Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999; 10:375-380
14. Saito M, Ishimitsu T, Minami J, et al. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167:73-79
15. Thor M, Yu A, Swedenborg J. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thromb Res 2002; 105:379-383
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502
17. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421
18. Matsuo S, Takahashi H. Practical application of receiver operating characteristic curve on laboratory diagnosis [in Japanese]. Rinsho Byori 1994; 42:585-590
19. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-2011
20. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843
21. Ridker PM, Stampfer MJ, Rifai N. Novel risk Factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485
22. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70
23. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104:992-997
24. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999; 84:459-461
25. Zhou YF, Csako G, Grayston JT, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumonias. Am J Cardiol 1999; 84:595-598
26. de Winter RJ, Heyde GS, Koch KT, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002; 23:960-966
27. Dibra A, Mehilli J, Schwaiger M, et al. Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. Eur Heart J 2003; 24:1128-1133
28. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98:2370-2376
29. Kornowski R, Hong MK, Tio FO, et al. In-sent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31:224-230
30. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513-520
31. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418
32. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease; principal results; EUROASPIRE study group. European action on secondary prevention through intervention to reduce events. Eur Heart J 1997; 18:1569-1582
33. Ess SM, Szucs TD. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease: an analysis in Germany and Italy. Ital Heart J 2001; 2:181-188
34. Jialal I, Devaraj S. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001; 116(Suppl):S108-S115
35. Gaspardone A, Versaci F, Proietti I, et al. Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Am J Cardiol 2002; 90:786-789
36. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-1965
37. Home BD, Muhlestein JB, Carlquist JF, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003; 107:258-263
38. van Wissen S, Trip MD, Smilde TJ, et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002; 165:361-366
39. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772
40. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331:417-424
41. Ueda S, Ikeda U, Yamamoto K, et al. C-reactive protein as a predictor of cardiac rupture after acute myocardial infarction. Am Heart J 1996; 131:857-860
42. Anzai T, Yoshikawa T, Asakura Y, et al. Effect on short-term prognosis and left ventricular function of angina pectoris prior to first Q-wave anterior wall acute myocardial infarction. Am J Cardiol 1994; 74:755-759